American Association for Cancer Research Virtual Annual Meeting II

American Association for Cancer Research Virtual Annual Meeting II

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly diagnosed, MGMT-unmethylated glioblastoma

American Association for Cancer Research Virtual Annual Meeting II

American Association for Cancer Research Virtual Annual Meeting II

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting

 American Association for Cancer Research Virtual Annual Meeting II

American Association for Cancer Research Virtual Annual Meeting II

Dianhydrogalactitol (VAL-083) synergizes with topoisomerase inhibitors to overcome homologous recombination repair activity in glioblastoma and prostate cancer cells

American Association for Cancer Research Virtual Annual Meeting II

American Association for Cancer Research Virtual Annual Meeting II

Dianhydrogalactitol (VAL-083) exhibits strong efficacy in GBM tumors with different epigenetic background and treatment history

Luxembourg Institute of Health

Luxembourg Institute of Health

Efficacy of VAL-083 in primary and recurrent brain tumor biopsies. VAL-083 showed consistent and superior anti-tumor activity against MGMT-unmethylated tumors in comparison to temozolomide

Society for Neuro-Oncology Annual Meeting 2019

Key Opinion Leader Event Audio
Nov 22, 2019
Society for Neuro-Oncology Annual Meeting 2019

Society for Neuro-Oncology Annual Meeting 2019

Key Opinion Leader Event Transcript

Society for Neuro-Oncology Annual Meeting 2019

Society for Neuro-Oncology Annual Meeting 2019

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Society for Neuro-Oncology Annual Meeting 2019

Society for Neuro-Oncology Annual Meeting 2019

Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM: Half-Way Report

AACR Annual Meeting 2019

AACR Annual Meeting 2019

Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo